A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 24
Summary
- Conditions
- Alzheimer's Disease
- Brain Diseases
- Central Nervous System Diseases
- Cognitive Impairment
- Dementia
- Mild Cognitive Impairment
- Tauopathies
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: RandomizedIntervention Model: Sequential AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 50 years and 75 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04445831
- Collaborators
- Janssen Research & Development, LLC
- Investigators
- Principal Investigator: Philip Scheltens, MD Amsterdam UMC Alzheimer Center de Boelelaan Amsterdam The Netherlands
Get Well Soon